ZYBT - היקף החוב לטווח ארוך Jilin Zhengye Biotechnology

This price chart for Zhengye Biotechnology (ZYBT) illustrates the performance of the veterinary vaccine producer. Its success is driven by demand from Chinese farms and strict sanitary controls, with an operating margin of 0.00. Revenues depend on livestock populations in the PRC and government contracts, while growth is driven by R&D investments and new certifications. Experienced executives effectively navigate bureaucratic complexities by implementing advanced biological products to protect the agricultural sector.

For Zhengye Biotechnology (ZYBT), which ensures global food security through veterinary innovations, an analysis of long-term liabilities determines the balance between expansion and sustainability. The organization's long-term financial debt metric aggregates all credit obligations with a maturity of more than one year. A stable trend in this metric confirms the systematic funding of vaccine development without critical liquidity risks. Investors should view this level as an indicator of capital maturity and the business's ability to scale its biotechnological developments.